

ISPOR 2019

PROGRAM

The Leading Global Conference for Health Economics and Outcomes Research

May 18-22

New Orleans Ernest N. Morial Convention Center
New Orleans, LA, USA

*Rapid. Disruptive. Innovative:
A New Era in HEOR*

 ISPOR



Join colleagues to discuss the latest trends in health economics and outcomes research (HEOR) and help shape the future of HEOR.

ISPOR is the leading scientific and educational organization for HEOR and its use in healthcare decision making.

Learn new methods and novel applications in the conduct and use of HEOR.

Engage with recognized global experts in the field.

Network with colleagues, collaborators, and clients.

Share your research and ideas with other ISPOR members in an open and neutral environment.

Stay current on emerging trends in healthcare.

Advance your career through active participation (eg, attend an ISPOR Short Course or a New Professional event).

Why Attend ISPOR 2019?

ISPOR 2019 will provide a forum for discussion and dissemination of HEOR information for more than 4000 delegates. The conference is a great opportunity to present your work, collaborate and network with colleagues in the field, and hear about innovative research methods and new health policy developments. Reflecting on revolutionary transformations affecting today's healthcare, ISPOR New Orleans will address medical technology development, health technology assessment, and policy and clinical decision making while exploring the theme *Rapid. Disruptive. Innovative: A New Era in HEOR*.

Who Attends?

The ISPOR sphere of influence engages global leaders in the international HEOR community, including policy makers, regulators, researchers, academicians, health technology developers, payers, decision makers, and patient groups. This multistakeholder group is invested in using science and research to make better healthcare decisions.

#ISPORAnnual

Trending topics:

Real-World Evidence • Digital Health • Value Assessment Frameworks • Machine Learning and Artificial Intelligence

- Clinical Outcomes Assessment
- Patient Preferences • Health Technology Assessment
- Biosimilars • Rare Disease
- Personalized Medicine
- Patient-Focused Drug Development • Medical Devices
- Health State Utility Estimates
- Oncology • Patient Engagement • Optimization Methods in Healthcare Research
- Gene Therapies and Curative Treatments • Patient-Reported Outcomes • Price Transparency for Healthcare Goods and Services • Big Data Analysis
- Drug Pricing and Spending
- Value Based Contracts

Register by April 9, 2019 and SAVE!

www.ispor.org

Make the most of ISPOR 2019!

PROGRAM

ISPOR 2019 features 2000+ presentations!

The program offers scientific topics of interest at multiple session times and in a variety of presentation formats.

Pre-Conference Short Courses are training courses offered across 7 HEOR key topic areas. The skill level ranges from introductory to experienced, and continuing education credits are available. *Separate registration is required.*

Plenary Sessions feature thought-provoking discussions on challenging topics related to healthcare policy, the application of HEOR in healthcare decision making, or methodology.

Spotlight Sessions (SP) highlight timely topics in HEOR and promote innovative areas of interest to the ISPOR community.

Issue Panels (IP) introduce debate with multistakeholder perspectives on new or controversial issues in HEOR.

Workshops (W) discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported outcomes, patient preferences, and healthcare policy.

Podium Presentations (P) consist of four 15-minute outcomes research presentations on a single topic.

Poster Presentations contain approximately 350 research posters per session arranged by disease, topic, or healthcare intervention with a scheduled author discussion hour.

Symposia are sponsored presentations related to ISPOR's mission. The sponsor organization selects a subject of interest to delegates and arranges suitable speakers.

NETWORKING

Connect with over 4000 ISPOR members, colleagues, collaborators, and clients.

- Meet with experts, clients, and other attendees. Schedule meetings via the ISPOR2019 mobile app and web platform (available approximately 1 month prior to the conference).
- Engage in session discussions with colleagues during the morning and afternoon coffee breaks or during lunch in the Poster and Exhibit Hall.
- Explore the Exhibit Hall and find products and services that meet your needs.
- Network with student members worldwide at roundtables, showcases, receptions, and more.

ISPOR GROUPS

Collaborate with members of your ISPOR groups.

ISPOR Regional Groups (Chapters, Networks, and Consortia): Join the educational, research, and policy-related activities of these groups and meet other HEOR professionals from your region of the world.

ISPOR Scientific and Health Policy Groups (Task Forces, Special Interest Groups, and Council Working Groups): Collaborate with members of these groups and participate in the development of ISPOR knowledge products, such as ISPOR Good Practices for Outcomes Research Task Force Reports, manuscripts for *Value in Health*, and online tools used by decision makers and researchers around the world.

New Professionals: Attend the New Professional event "Career Advice Across the Globe," which touches on a different career-related topic for each conference. The event aims to provide a global perspective for those who are new to the field of HEOR. New Professionals also are encouraged to attend booth events specifically catering to this member type.

Students: Network with international student members! Join us at the Student Research Competition, Student and Faculty Icebreaker Reception, Student Research Spotlight, and the Student Roundtable — all highly attended events! The Student Network also will host a few booth events at the ISPOR booth, which we encourage students to attend to learn more. Not part of a Student Chapter currently? For more information on starting a chapter, visit www.ispor.org/member-groups/students/start-a-student-chapter.

Thank you to the following ISPOR 2019 Supporters and Sponsors:

(Sponsors as of press time)

Gold:

Evidera | PPD
HealthCore
Pharmerit International

Silver:

Certara | Evidence & Access
TriNetX
Veradigm

Bronze:

Kantar
Precision Xtract / Precision for Value
Prognos
RTI (h)s Health Solutions

Interested in becoming a conference Sponsor?

See www.ispor.org/ISPOR2019sponsorship for available sponsorships.

The ISPOR 2019 Exhibit Hall provides the perfect setting for attendees to meet professionals in the health economics and outcomes research (HEOR) field, discuss the latest trends, and learn from industry experts.

EXHIBIT HALL HOURS

Monday, May 20, 10:30AM - 7:30PM
Exhibitor Reception 6:00PM - 7:30PM

Tuesday, May 21, 10:30AM - 7:30PM
Exhibitor Reception 6:00PM - 7:30PM

Wednesday, May 22, 9:30AM - 2:00PM

ISPOR GENERAL BUSINESS MEETING: Tuesday, May 21 from 1:00PM - 2:00PM

Plenary Sessions Featured at ISPOR 2019

FIRST PLENARY SESSION: MONDAY, MAY 20, 8:30AM - 10:30AM

The Dawn of Disruption in the Health Sector: Will Innovative Technologies Require Innovative Ways of Thinking?

The healthcare sector has recently witnessed several landmark moments in the development of the next generation of medical care. While media attention has rightly focused on milestone regulatory approvals for several groundbreaking curative treatments and devices, the best is likely yet to come: over 2600 clinical trials of gene therapies are either completed or ongoing; nearly 1000 trials of regenerative medicine are in progress worldwide; and more than 7000 trials for medical devices ranging from bionic eye brain implants to spinal cord stimulators are underway.

Disruption will not be limited to drugs and devices, however. Advances in the applications of 3-D printing as well as artificial intelligence have the potential to generate powerful new tools for disease prevention, diagnosis, and treatment. In short, innovations that have long been the stuff of science fiction may no longer be distant points on the horizon. Are we entering a "golden age" of disruptive innovation in medical care? What new challenges and opportunities will these technologies bring? How can a health sector attuned to an old way of doing things truly prepare for treatments that break the mold? This plenary session will begin with an overview of the current and future landscape followed by a discussion among leading experts. Emerging challenges and opportunities presented by disruptive technologies will be addressed from the perspective of a variety of stakeholders such as payers, manufacturers, and patients.

SECOND PLENARY SESSION: TUESDAY, MAY 21, 8:30AM - 10:30AM

Medical Device Innovation and Regulation: Turbocharged for Success?

The medical implants market is one of the fastest-growing in healthcare. Yet alongside this rapid growth, the industry is facing increasing calls for regulation and oversight. As the demand for innovative medical devices accelerates, how can regulators ensure the highest level of health protection without hindering research and growth in the sector? This tension emerges from the two forces shaping the medical devices market: companies who are driving innovation, eager to bring needed new advances to patients and clinicians as quickly as possible and the regulators, responsible for governing the parameters of these advances.

So how will the latest legislation fare? The new EU Medical Devices Regulation ((EU) 2017/745) will come into force on May 26, 2020 and is intended to "ensure a high level of safety and health while supporting innovation." Other regulators such as the FDA are also instituting major changes to their medical device regulations. How will these new regulations better guarantee patients' safety and strengthen confidence on the uptake and diffusion of medical devices? This plenary will explore how our healthcare systems navigate these controversies and identify implications and opportunities for the HEOR community, including the generation of relevant real-world evidence to support better decision-making as well as what further regulations are needed. Finally, the panel will consider how such systems can evolve to keep up with the rapidly-innovating world of medical devices.

THIRD PLENARY SESSION: WEDNESDAY, MAY 22, 11:00AM - 12:30PM

Is Affordability Driving a Need to Revolutionize Drug Pricing?

Promoting rapid and equitable access to promising therapies in an affordable manner is a laudable goal for all health systems. However, with the explosion of high cost, disruptive, and innovative drugs — many of which are promising a cure — payers are facing a crisis of affordability. We are in an era with six-figure cancer treatments, curative and costly gene therapies, ultra-high cost drugs for treating orphan diseases, and even expensive drugs for more common diseases. It is an exciting and promising time for patients, clinicians, and pharmaceutical companies, and a challenging time for payers who must now look beyond cost-effectiveness to address affordability.

The ISPOR 2019 Top 10 HEOR Trends report identified drug spending and pricing as the top trend. In the United States, President Trump launched his Blueprint to Lower Drug Prices in May 2018, and a recent paper from the University of Chicago reported that average total drug spending per hospital admission increased 18.5% between 2015 and 2017. Affordability of pharmaceuticals has become a truly global issue. Is it time for a revolution in how we price, fund, and manage drugs? Are there innovative approaches that can promote access, manage affordability, and still foster innovation? What can be done to significantly improve the transparency of drug prices? How do we ensure equitable access to low- and middle-income countries and disadvantaged populations?

CONFERENCE PROGRAM COMMITTEE

ISPOR thanks the Conference Program Committee for its contributions in developing the scientific community's leading HEOR program.

PROGRAM COMMITTEE CO-CHAIRS

Jalpa Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA

Brian O'Rourke, PharmD, CADTH, Ottawa, ON, Canada

Rosanna Tarricone, PhD, MSc, Bocconi University, Milan, Italy

RESEARCH COMMITTEE CO-CHAIRS

Patrick Hopkinson, Bristol-Myers Squibb, Pharmaceuticals, Uxbridge, UK

Lori McLeod, PhD, RTI Health Sciences, Research Triangle Park, NC, USA

Ebere Onukwugha, MS, PhD, University of Maryland, School of Pharmacy, Baltimore, MD, USA

Ya-Chen Tina Shih, PhD, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

Jessica Daw, PharmD, MBA, UPMC Health Plan, Pittsburgh, PA, USA

Hemant Phatak, PhD, EMD Serono, Inc., Rockland, MA, USA

Lotte Steuten, PhD, MSc, Office of Health Economics, London, England

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Bruce Gingles, BA, COOK Medical, Inc., Bloomington, IN, USA

K. Jack Ishak, PhD, MSc, Evidera, Montreal, QC, Canada

Maureen Smith, MEd, CORD and PCORI, Ottawa, ON, Canada

Pre-Conference Short Course Program

Learn. Apply. Advance. Attend any session, including one of our 4 NEW courses!

The ISPOR HEOR Short Course Program, offered in conjunction with ISPOR conferences around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge in 7 key topic areas (“tracks”) related to HEOR. Short courses (many with hands-on training opportunities) range from introductory to experienced and are taught by leading experts in the field. *Separate registration is required for Short Courses.*

Short Courses are offered Saturday, May 18 and Sunday, May 19 in the following topic areas:

Health Policy & Regulatory

Elements of Pharmaceutical/Biotech Pricing 1 — Introduction
 Case Studies in Pharmaceutical/Biotech Pricing 2 — Advanced
NEW! US Healthcare System and Its Approach to Value and Affordability
 Risk-Sharing/Performance-Based Arrangements for Drugs and other Medical Products
NEW! Market Access & Value Assessment of Medical Devices

Methodological & Statistical Research

Bayesian Analysis: Overview and Applications
 Introduction to Modeling Methods
 Modeling: Design and Structure of a Model
 Using DICE Simulation for Health Economic Analyses
 Advanced Decision Modeling for Health Economic Evaluations

Health Technology Assessment

Introduction to Health Technology Assessment
 A Health Economics Approach to US Value Assessment

Patient-Centered Research

Utility Measures
 Introduction to Patient-Reported Outcomes
NEW! Health State Utility (HSU) Recommendations for Identification and Use of HSU Data in Cost-Effectiveness Modeling
 Stated Preference Methods — Part 1
 Advanced Patient-Reported Outcomes
 Patient-Reported Outcomes: Item Response Theory
 Stated Preference Methods — Part 2
 Preference Data for Patient-Centric Benefit Risk Analysis

Study Approaches

Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources
 Use of Propensity Scores in Observational Studies of Treatment Effects
 Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research
 Applications in Using Large Databases
 Use of Instrumental Variables in Observational Studies of Treatment Effects
 Network Meta-Analysis

Real World Data & Information Systems

NEW! Tools for Reproducible Real-World Data Analysis
 Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials

Economic Evaluation

Introduction to Health Economics and Outcomes Research
 Value of Information: Active Learning, Modeling Tools, and Applications
 Statistical Methods in Economic Evaluations
 Cost-Effectiveness Analysis Alongside Clinical Trials
 Budget Impact Analysis 1 — A 6-Step Approach
 Budget Impact Analysis 2 — Applications and Design Issues

Select courses require use of your personal laptop.

SHORT COURSE FEES

ALL-DAY COURSES

Thru April 9, 2019

Standard: \$700
 Clinical/Government/Academia: \$500
 Full-Time Student: \$200
 Patient Representative: \$200

After April 9, 2019

Standard: \$800
 Clinical/Government/Academia: \$600
 Full-Time Student: \$250
 Patient Representative: \$250

HALF DAY COURSES

Thru April 9, 2019

Standard: \$350
 Clinical/Government/Academia: \$250
 Full Time Student: \$100
 Patient Representative: \$100

After April 9, 2019

Standard: \$400
 Clinical/Government/Academia: \$300
 Full-Time Student: \$125
 Patient Representative: \$125

CONFERENCE ENHANCEMENT FEES

Short Course Continuing Education Accreditation (CPE & CME): \$125

SEPARATE SHORT COURSE REGISTRATION IS REQUIRED.

See www.ispor.org/ISPOR2019shortcourses for Short Course schedule and descriptions, and to register.

Conference Program*

ISPOR 2019 features 3 thought-provoking plenary sessions and more than 2000 presentations in the form of workshops, issue panels, symposia, podium presentations, and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real-world data, and clinical-, economic-, and patient-reported outcomes.
Conference registration is required.

Saturday May 18

8:00AM - 5:00PM **SHORT COURSES** *(Separate registration required)*

5:30PM - 6:30PM **EDUCATIONAL SYMPOSIUM**
 De-Risking Risk Sharing: Enabling Payer-Pharma Interactions and Value-Based Contracting With RWE *(Sponsored by AETION)*

Sunday May 19

8:00AM - 5:00PM **SHORT COURSES** *(Separate registration required)*

5:00PM - 7:00PM **ISPOR STUDENT RESEARCH COMPETITION**

5:30PM - 6:30PM **EDUCATIONAL SYMPOSIUM**
 Able to Cure, Able to Pay: Closing the Widening Gap
(Sponsored by National Pharmaceutical Council)

6:30PM - 7:30PM **PRESIDENT'S RECEPTION** (BY INVITATION ONLY)

7:00PM - 8:00PM **ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION**

7:30PM - 9:30PM **ISPOR AWARDS BANQUET**
 The inaugural ISPOR Awards Banquet will highlight member contributions to excellence in the science of HEOR and exemplary service to the Society. *Hilton New Orleans Riverside. Limited tickets available/\$150 per person. Ticket includes entrance to President's Reception. Separate registration required.*

Monday May 20

7:15AM - 8:15AM **EDUCATIONAL SYMPOSIUM**
 21st Century FDA - Exploring the Rise of Real-World Evidence
(Sponsored By Cardinal Health)

8:30AM - 10:30AM **WELCOME & FIRST PLENARY SESSION**
THE DAWN OF DISRUPTION IN THE HEALTH SECTOR: WILL INNOVATIVE TECHNOLOGIES REQUIRE INNOVATIVE WAYS OF THINKING?

10:30AM - 2:00PM **RESEARCH POSTERS — SESSION 1**

10:30AM - 7:30PM **POSTER & EXHIBIT HALL HOURS**

11:00AM - 12:00PM **BREAKOUT SESSION 1**

- IP1: The Controversial QALY: Is There a Middle Ground in the Debate?
- IP2: Replication of Randomized Controlled Trials Using Real World Data: What Does Good Look Like?
- IP3: Can Health Plans Address the Challenges to Accommodating the Growing Number of Orphan Drugs Entering the Marketplace?
- P1: Artificial Intelligence Studies

P2: Cardiovascular Studies

W1: Early Prediction of Survival Outcomes—Modeling Approaches for Translation of Tumor Response to Long-Term Clinical Benefits in Early Stage Cancer

W2: An Analytic Approach to Incorporating Patient Preferences into Value Elements for Economic Evaluation

12:00PM - 1:30PM **LUNCH IN THE POSTER & EXHIBIT HALL**

12:00PM - 2:00PM **EXHIBITS AND RESEARCH POSTER PRESENTATIONS VIEWING — SESSION 1**

12:30PM - 1:30PM **EDUCATIONAL SYMPOSIUM**
 Challenges of Economic Modeling in Rare Diseases and Assessment of Value in SMA *(Sponsored by Biogen)*

1:00PM - 2:00PM **POSTER AUTHOR DISCUSSION HOUR — SESSION 1**

2:15PM - 3:15PM **SPOTLIGHT SESSION**
 SP1: Global Developments in Artificial Intelligence and Machine Learning in Healthcare
 SP2: 20th Anniversary of *Value in Health* Session
 SP3: Beyond One Size Fits All: The Importance of Heterogeneity in Preference Research

3:15PM - 3:45PM **BREAK, RESEARCH POSTERS — SESSION 2 & EXHIBITS**

3:30PM - 4:30PM **ISPOR STUDENT RESEARCH SPOTLIGHT**

3:30PM - 7:00PM **RESEARCH POSTERS — SESSION 2**

3:45PM - 4:45PM **BREAKOUT SESSION 2**
 IP4: Proactive Post-Market Surveillance, 510(K) Update, and Real-World Evidence: Can It Improve Patient Safety, Outcomes and Provide a Competitive Edge?

IP5: Are Novel Concepts of Value Ready for Prime Time?
 IP6: The Clinical and Economic Value of Genetic Sequencing in Cancer Care: Are Next Generation Sequencing (NGS)-Based Tests Clinically Useful and Cost Effective in Real World Settings? What is Necessary to Fully Realize Their Value?

P3: Modeling & Simulation Studies

P4: Rare & Orphan Diseases Studies

W3: Using PFS to Determine the Cure Potential of New Innovative Therapies in DLBCL

W4: Proactive: Linking Design, Analysis and Interpretation of PROs in Clinical Trials

5:00PM - 6:00PM **BREAKOUT SESSION 3**

- IP7: How Much Should We – And Can We – Pay for Gene Therapies?
- IP8: Can We Make Global Value Assessments More Flexible and Comprehensive?
- IP9: Are Standard HTA Approaches to Cost-Effectiveness Modeling Appropriate for Tumor-Agnostic Oncology Products With Basket Trials?
- P5: Adherence, Persistence and Compliance Studies

P6: Reimbursement and Access Policy Studies
W5: Quantitative Patient Preferences and Values with Limited Information: Lessons from the Non-Health Benefits-Transfer Literature
W6: Artificial Intelligence for Next Generation Epidemiology and Outcomes Research

5:00PM - 6:00PM **ISPOR NEW PROFESSIONAL EVENT — CAREER ADVICE ACROSS THE GLOBE**

6:00PM - 7:00PM **POSTER AUTHOR DISCUSSION HOUR — SESSION 2**

6:00PM - 7:30PM **EXHIBITORS' OPEN HOUSE RECEPTION**

7:30PM - 9:00PM **ISPOR GLOBAL NETWORKS RECEPTION**

Tuesday May 21

7:15AM - 8:15AM **EDUCATIONAL SYMPOSIUM**
 Concept to Coverage: Utilization of Value Assessment Frameworks in Payer Decision-Making *(Sponsored by Xcenda)*

8:30AM - 10:30AM **WELCOME & SECOND PLENARY SESSION**
MEDICAL DEVICE INNOVATION AND REGULATION: TURBOCHARGED FOR SUCCESS?

10:30AM - 2:00PM **RESEARCH POSTERS — SESSION 3**

10:30AM - 7:30PM **POSTER & EXHIBIT HALL HOURS**

11:00AM - 12:00PM **BREAKOUT SESSION 4**
IP10: The Rise of ICER Means the Loss of Choice: True, False or Uncertain?
IP11: MCDA or Weighted CEA Based on the QALY? Which is the Future for HTA Decision Making?
IP12: Controversies Around the Use of Patient-Reported Measures in Oncology: What are the Benefits, Risks, and Barriers to Implementing PR-PMS in Value-Based Payment Programs?
P7: Clinical Outcomes Assessment Studies
P8: Medical Technology Studies
W7: How to Tackle the Estimation of Treatment Impact in the Presence of Differential Withdrawal and Missing Data Among Study Arms?
W8: Assessing the Value of Rare Disease Treatments: Global Lessons from Recent Case Studies

12:00PM - 1:30PM **LUNCH IN THE POSTER & EXHIBIT HALL**

12:00PM - 2:00PM **EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING — SESSION 3**

12:30PM - 1:30PM **EDUCATIONAL SYMPOSIUM**
 Cell and Gene Therapy - Value and Access *(Sponsored by Analysis Group)*

1:00PM - 2:00PM **POSTER AUTHOR DISCUSSION HOUR — SESSION 3**

1:00PM - 2:00PM **ISPOR GENERAL BUSINESS MEETING**

2:15PM - 3:15PM **BREAKOUT SESSION 5**
IP13: To Register or Not Register (The Protocol). That is the Question in Observational and Big Data Studies, Economic Models, and Cost-Effectiveness Analysis

IP14: How Can New Outcomes Such as the Ones Derived from Wearables or Patient Experience Reports be Useful in Reimbursement and Coverage Decisions?
IP15: Single-Arm Trials of Novel Therapies. Too Good for Approval, But Not Good Enough for Reimbursement?
P9: Infectious Disease Studies
P10: Drug Related Public Health Studies
W9: Use of Real-World Data to Extrapolate Survival Estimates for Cost-Effectiveness Analyses in Oncology
W10: Developing Standard Core Sets of Clinical Outcome Assessments and Their Related Endpoints for Specific Disease Indications

3:15PM - 3:45PM **BREAK & EXHIBITS**

3:30PM - 4:30PM **ISPOR STUDENT ROUNDTABLE EVENT — CURRENT TRENDS IN HEOR**

3:30PM - 7:00PM **RESEARCH POSTERS — SESSION 4**

3:45PM - 4:45PM **BREAKOUT SESSION 6**
IP16: Real Option Value for Drugs: Is it Really an Option?
IP17: Gene Therapy in Hemophilia: Can We Balance the Priorities of Patients, Providers, and Payers?
IP18: Gazing into the HEOR Crystal Ball: What Might Be the Future Directions for HEOR in the 2020s?
P11: Comparative and Cost Analysis
P12: Real-World Data Studies
W11: Are We Capturing the Entire Picture? — Family Spillover Effects in Economic Evaluation
W12: Approaches to Advance the Value of Patient Preference Information in Medical Product Evaluation

5:00PM - 6:00PM **BREAKOUT SESSION 7**
IP19: How Should Data on Social Determinants of Health Be Best Used to Improve Health Outcomes and Reduce Disparities?
IP20: How is the "Regulatory-Grade" Criterion Defined and What Does it Take for RWE to Meet It?
P13: Oncology Studies
P14: Neurological Disorders Studies
W13: Leveraging Patient-Provided Information to Improve Real-World Evidence: Getting to Good Practices on HOW
W14: Multicriteria Decision Analysis for Health Care Decision Making in The United States: Active Learning Through a Real-Time MCDA Case Study
W15: Excel With Your Economic Models Using R

5:00PM - 6:15PM **ISPOR WOMEN IN HEOR INITIATIVE OPEN MEETING**

6:00PM - 7:00PM **POSTER AUTHOR DISCUSSION HOUR — SESSION 4**

6:00PM - 7:30PM **EXHIBITORS' WINE & CHEESE RECEPTION**

6:30PM - 7:30PM **ISPOR MEET THE WOMEN IN HEOR SPEAKERS RECEPTION**

Wednesday May 22

7:15AM - 8:15AM **EDUCATIONAL SYMPOSIUM**
 Assessing the Value of Rare Disease Treatments: Global Lessons from Recent Case Studies *(Sponsored by Amgen)*

8:30AM - 9:30AM BREAKOUT SESSION 8

IP21: Replicable and Robust Database Evidence: What Does It Look Like?

IP22: How Can Biosimilars Make Headway in the USA? Dealing with The Legal, Regulatory, Payer Coverage Policy, and Access Challenges

IP23: Can an Alternative Evaluation Approach, Addressing the Needs of the Purchaser Rather Than the Payer, be the Answer to Standardizing the Information Set Used to Make Healthcare Purchasing Decisions?

P15: Cost and Resource Use Studies

P16: Treatment Patterns

W16: Eliciting and Applying Patient Preference Information for Regulatory Decision-Making: What Have We Learned and Where Are We Going?

W17: New Wine in Old Bottles: Changing Values for Health – EQ-5D as a Case Study

9:30AM - 2:00PM POSTER & EXHIBIT HALL HOURS

9:30AM - 2:00PM RESEARCH POSTERS — SESSION 5

9:45PM - 10:45PM BREAKOUT SESSION 9

IP24: Can Meaningful Models be Constructed for Rare Conditions?

IP25: Is There an Urgent Need to Explore the Opportunities and Challenges of Wide Use of RWE in Medical Devices?

IP26: Could Formal HTA Be the Solution to High Healthcare Costs in the USA?

P17: Conceptual Papers

P18: Diabetes Studies

W18: Generating External Control Arms Using Real-World Data: Analytic Challenges and Recommendations

W19: Health Economists Can Help Reduce the Uncertainty of the Risk in Value-Based Contracts!

10:45PM - 11:00AM BREAK

11:00AM - 12:30PM WELCOME & THIRD PLENARY SESSION IS AFFORDABILITY DRIVING A NEED TO REVOLUTIONIZE DRUG PRICING?

12:45PM - 1:45PM POSTER AUTHOR DISCUSSION HOUR — SESSION 5

12:30PM - 1:45PM EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING — SESSION 5

12:30PM - 2:00PM LUNCH IN THE POSTER & EXHIBIT HALL

2:00PM - 3:00PM BREAKOUT SESSION 10

W20: Improving Patient Access to Life-Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars?

W21: Identifying and Addressing Barriers to the Adoption of Standardized Outcome Measures in Patient Registries and Clinical Practice

W22: Beyond Trial Replication: Using Real-World Data to Bridge the Efficacy-Effectiveness Gap in Healthcare

W23: Getting the Most Out of Value Based Contracting for Medical Devices

W24: Patient-Focused Drug Development: Operational Considerations for Conducting Qualitative Research in Special Populations

**Program subject to change. Please visit the conference website for the most current information.*

CONFERENCE REGISTRATION FEES *Early Registration Deadline: April 9, 2019*

REGISTRATION FEES	Through April 9, 2019		After April 9, 2019	
	Member	Non-member	Member	Non-member
Standard	\$900	\$1125	\$1000	\$1225
Clinical Practitioners (Clinical Practice, Hospital)	\$675	\$900	\$775	\$1000
Full-Time Government and Academia Member	\$575	\$800	\$675	\$900
Patient Representative	\$200	\$285	\$250	\$335
Full-Time Students (with current enrollment docs)	\$200	\$295	\$250	\$345
1 Day Registration (per day) May 20, May 21, May 22	\$400	\$625	\$500	\$725

CONFERENCE ENHANCEMENT FEES

ISPOR Awards Banquet: Sunday, May 19, 7:30PM - 9:30PM—Hilton New Orleans Riverside. Ticket includes entrance to President's Reception and the Awards Banquet. \$150 per person/LIMITED SEATS AVAILABLE.

Register at: www.ispor.org/ISPOR2019Reg

Hotel/Venue Information: ISPOR 2019 will be held at the New Orleans Ernest N. Morial Convention Center, <http://www.mccno.com/>, conveniently located for easy access by air, rail, or car. The convention center is an approximate 20-minute drive from the Louis Armstrong International Airport; and 1.2 miles using Amtrak rail services to New Orleans Union Passenger Terminal.

Registration will be located in the Lobby entrance to Hall H in the Convention Center. Posters and exhibits will be in Hall H.

ISPOR has negotiated discounted rates with prime hotels. **Attendees may reserve accommodations until Monday, April 15, 2019**, by visiting the Venue and Hotel Information page on the ISPOR 2019 website at www.ispor.org/ISPOR2019venue. Accommodations are available on a first come, first served basis; subject to availability. **Book early to secure your discounted rate.**



ISPOR—The professional society for health economics and outcomes research
505 Lawrence Square Blvd, South
Lawrenceville, NJ 08648 USA

ISPOR 2019

May 18-22
New Orleans, LA, USA

Rapid. Disruptive. Innovative:
A New Era in HEOR



Register by April 9 for early bird rates.
Discounted hotel rates until April 15th, based on availability.

